SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics
Portfolio Pulse from
Faruqi & Faruqi, LLP is investigating potential securities law violations by Intellia Therapeutics related to its Phase 1/2 study for NTLA-3001. The law firm alleges that the company made false or misleading statements about its clinical timeline and failed to disclose declining interest in viral-based editing. On January 9, 2025, Intellia announced it would discontinue NTLA-3001, cut 27% of its workforce, and incur $8 million in restructuring charges, causing its stock to drop 15.14%.
April 10, 2025 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Potential securities class action lawsuit alleges company misled investors about clinical study and strategic direction, leading to stock price decline and workforce reduction.
The lawsuit and strategic restructuring suggest significant operational challenges, potential financial strain, and loss of investor confidence, which could negatively impact the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100